Carnitine replacement in end-stage renal disease and hemodialysis

被引:51
作者
Calvani, M
Benatti, P
Mancinelli, A
D'Iddio, S
Giordano, V
Koverech, A
Amato, A
Brass, EP
机构
[1] Sigma Tau Pharmaceut Co, Dept Sci, I-00400 Rome, Italy
[2] Sigma Tau Res, Gaithersburg, MD USA
[3] Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA
来源
CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT | 2004年 / 1033卷
关键词
carnitine; acylcarnitines; end-stage renal disease; uremia; hemodialysis;
D O I
10.1196/annals.1320.005
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In patients with chronic renal failure, not yet undergoing hemodialysis (HD), plasma acylcarnitines accumulate in part due to a decreased renal clearance of esterified carnitine moieties. In these patients, a high acyl-carnitine/free-carnitine ratio is usually found in plasma. Patients undergoing maintenance HD, usually present With plasma carnitine insufficiency, due to accumulation of metabolic intermediates combined with impaired carnitine biosynthesis, reduced protein intake and increased removal via HD. Plasma carnitine concentrations rapidly decrease to 40% of baseline level during the dialysis session, with a slow restoration of the carnitine concentration during the interdialytic period, mainly from organs of storage (skeletal muscle). Dietary intake also plays an important role in carnitine homeostasis of HD patients since the prevalence of malnutrition ranges from 18% to 75% of these cases. This could differentially affect various body compartments, with clinical consequences such as impaired muscle function, decreased wound healing, altered ventilatory response, and abnormal immune function. Repeated hemodialytic treatments are associated with decreased carnitine stores in skeletal muscle. The administration of intravenous L-carnitine (LC) postdialysis replenishes the free carnitine removed from the blood and contributes to replenishment of muscle carnitine content. LC supplementation in selected uremic patients may yield clinical benefits by ameliorating several conditions, such as erythropoietin-resistant anemia, decreased cardiac performance, intradialytic hypotension, muscle symptoms, as well as impaired exercise and functional capacities. Furthermore, LC may positively influence the nutritional status of HD patients by promoting a positive protein balance, and by reducing insulin resistance and chronic inflammation, possibly through an effect on leptin resistance.
引用
收藏
页码:52 / 66
页数:15
相关论文
共 83 条
[1]  
Agroyannis B, 2002, DIALYSIS TRANSPLANT, V31, P106
[2]   MULTICENTER TRIAL OF L-CARNITINE IN MAINTENANCE HEMODIALYSIS-PATIENTS .2. CLINICAL AND BIOCHEMICAL EFFECTS [J].
AHMAD, S ;
ROBERTSON, HT ;
GOLPER, TA ;
WOLFSON, M ;
KURTIN, P ;
KATZ, LA ;
HIRSCHBERG, R ;
NICORA, R ;
ASHBROOK, DW ;
KOPPLE, JD .
KIDNEY INTERNATIONAL, 1990, 38 (05) :912-918
[3]  
AHMAD S, 1989, KIDENY INT, V38, P912
[4]  
AMATO A, 2000, CARNITINE THERAPY HE
[5]  
[Anonymous], CLIN EUR
[6]   Addition of L-carnitine to additive solution-suspended red cells stored at 4 degrees C reduces in vitro hemolysis and improves in vivo viability [J].
Arduini, A ;
Holme, S ;
Sweeney, JD ;
Dottori, S ;
Sciarroni, AF ;
Calvani, M .
TRANSFUSION, 1997, 37 (02) :166-174
[7]   EFFECT OF L-CARNITINE AND ACETYL-L-CARNITINE ON THE HUMAN ERYTHROCYTE-MEMBRANE STABILITY AND DEFORMABILITY [J].
ARDUINI, A ;
ROSSI, M ;
MANCINELLI, G ;
BELFIGLIO, M ;
SCURTI, R ;
RADATTI, GL ;
SHOHET, SB .
LIFE SCIENCES, 1990, 47 (26) :2395-2400
[8]   CORRELATION BETWEEN INCREASED SERUM AND TISSUE L-CARNITINE LEVELS AND IMPROVED MUSCLE SYMPTOMS IN HEMODIALYZED PATIENTS [J].
BELLINGHIERI, G ;
SAVICA, V ;
MALLAMACE, A ;
DISTEFANO, C ;
CONSOLO, F ;
SPAGNOLI, LG ;
VILLASCHI, S ;
PALMIERI, G ;
CORSI, M ;
MACCARI, F .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1983, 38 (04) :523-531
[9]   CARNITINE [J].
BIEBER, LL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1988, 57 :261-283
[10]   Role of fatty acids in the pathogenesis of insulin resistance and NIDDM [J].
Boden, G .
DIABETES, 1997, 46 (01) :3-10